Physician profile
George Lam
NPI 1467961565
$8,557.82
in general payments reported to CMS, 2019-2025
16 companies · $2,477 in 2025
The $2,477 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $655 · 2022: $1,493 · 2023: $1,426 · 2024: $2,508 · 2025: $2,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,363 · Education: $47.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,362.94 |
| Education | $47.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,234.17 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $1,776.59 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $872.04 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $605.24 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $592.34 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $503.45 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $478.64 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $464.04 | 2022-2023 | |
| Abiomed | $300.83 | 2024 | Impella |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $272.82 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $148.50 | 2021-2022 | |
| Medtronic, INC. | $123.31 | 2024 | Avalus |
| Axsome Therapeutics, INC. | $120.99 | 2024 | Auvelity |
| Lundbeck LLC | $27.91 | 2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $21.68 | 2025 | Qelbree |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $15.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.